Literature DB >> 23165494

Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor.

M Aljurf1, H Al-Zahrani, M T Van Lint, J R Passweg.   

Abstract

Matched related donor allo-SCT is the treatment of choice for patients with severe aplastic anemia (SAA) younger than 40 years of age. The standard conditioning regimen for such patients is cyclophosphamide with antithymocyte globulin. Unmanipulated BM is the best stem cell source for aplastic anemia patients going for SCT. Post-transplant GVHD prophylaxis with cyclosporine should be continued for 1 year. Early graft failure is rare but potentially life-threatening complication of SCT that can be managed with salvage SCT using more intense conditioning regimen.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23165494     DOI： 10.1038/bmt.2012.223

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  11 in total

Review 1.  Alternative donor transplants for severe aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia.

Authors:  Michael J Eckrich; Kwang-Woo Ahn; Richard E Champlin; Peter Coccia; Kamar Godder; John Horan; David Margolis; H Joachim Deeg; Mary Eapen
Journal:  Am J Hematol       Date:  2013-11-15       Impact factor: 10.047

3.  Antithymocyte globulin and transplants for aplastic anemia.

Authors:  Andrea Bacigalupo
Journal:  Haematologica       Date:  2017-07       Impact factor: 9.941

4.  Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.

Authors:  Nelli Bejanyan; Soyoung Kim; Kyle M Hebert; Natasha Kekre; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Sherif M Badawy; Amer Beitinjaneh; Jaap Jan Boelens; Miguel Angel Diaz; Christopher C Dvorak; Shahinaz Gadalla; James Gajewski; Robert Peter Gale; Siddhartha Ganguly; Andrew R Gennery; Biju George; Usama Gergis; David Gómez-Almaguer; Marta Gonzalez Vicent; Hasan Hashem; Rammurti T Kamble; Kimberly A Kasow; Hillard M Lazarus; Vikram Mathews; Paul J Orchard; Michael Pulsipher; Olle Ringden; Kirk Schultz; Pierre Teira; Ann E Woolfrey; Blachy Dávila Saldaña; Bipin Savani; Jacek Winiarski; Jean Yared; Daniel J Weisdorf; Joseph H Antin; Mary Eapen
Journal:  Blood Adv       Date:  2019-10-22

5.  Syngeneic transplantation in aplastic anemia: pre-transplant conditioning and peripheral blood are associated with improved engraftment: an observational study on behalf of the Severe Aplastic Anemia and Pediatric Diseases Working Parties of the European Group for Blood and Marrow Transplantation.

Authors:  Sabine Gerull; Martin Stern; Jane Apperley; Dietrich Beelen; Lorentz Brinch; Donald Bunjes; Andrew Butler; Arnold Ganser; Ardeshir Ghavamzadeh; Mickey B Koh; Mieczyslaw Komarnicki; Nicolaus Kröger; Johan Maertens; Alexei Maschan; Christina Peters; Montserrat Rovira; Henrik Sengeløv; Gerard Socié; Johanna Tischer; Rosi Oneto; Jakob Passweg; Judith Marsh
Journal:  Haematologica       Date:  2013-07-26       Impact factor: 9.941

Review 6.  Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT).

Authors:  Raheel Iftikhar; Parvez Ahmad; Regis de Latour; Carlo Dufour; Antonio Risitano; Naeem Chaudhri; Ali Bazarbachi; Josu De La Fuente; Britta Höchsmann; Syed Osman Ahmed; Usama Gergis; Alaa Elhaddad; Constantijn Halkes; Bassim Albeirouti; Sultan Alotaibi; Austin Kulasekararaj; Hazzaa Alzahrani; Tarek Ben Othman; Simone Cesaro; Ali Alahmari; Rawad Rihani; Salem Alshemmari; Amir Ali Hamidieh; Mohamed-Amine Bekadja; Jakob Passweg; Murtadha Al-Khabori; Walid Rasheed; Andrea Bacigalupo; Qamar-Un-Nisa Chaudhry; Per Ljungman; Judith Marsh; Riad El Fakih; Mahmoud Aljurf
Journal:  Bone Marrow Transplant       Date:  2021-05-19       Impact factor: 5.483

7.  Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin.

Authors:  Dan Yang; Jianmin Yang; Xiaoxia Hu; Jie Chen; Lei Gao; Hui Cheng; Gusheng Tang; Yanrong Luo; Weiping Zhang; Jianmin Wang
Journal:  Ann Transplant       Date:  2019-08-09       Impact factor: 1.530

8.  First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.

Authors:  Andrea Bacigalupo; Rosi Oneto; Hubert Schrezenmeier; Britta Hochsmann; Carlo Dufour; Seiji Kojima; Xiaofan Zhu; Xiaojuan Chen; Surapol Issaragrisil; Suporn Chuncharunee; Dae Chul Jeong; Sabrina Giammarco; Maria Teresa Van Lint; Yizhou Zheng; Carlos Vallejo
Journal:  Am J Hematol       Date:  2018-03-23       Impact factor: 10.047

9.  Stem cell transplantation in aplastic anemia: Impact on choices for first line therapy.

Authors:  Andrea Bacigalupo; Sabrina Giammarco
Journal:  Hemasphere       Date:  2019-06-30

10.  Better Failure-Free Survival and Graft-versus-Host Disease-Free/Failure Free Survival with Fludarabine-Based Conditioning in Stem Cell Transplantation for Aplastic Anemia in Children.

Authors:  Seung Hwan Im; Bo Ram Kim; Soo Min Park; Bo Ae Yoon; Tai Ju Hwang; Hee Jo Baek; Hoon Kook
Journal:  J Korean Med Sci       Date:  2020-02-24       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.